V
81.06
-6.23 (-7.14%)
| Previous Close | 87.29 |
| Open | 86.20 |
| Volume | 1,227,274 |
| Avg. Volume (3M) | 1,149,036 |
| Market Cap | 10,103,074,816 |
| Price / Book | 3.14 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Diluted EPS (TTM) | -4.60 |
| Total Debt/Equity (MRQ) | 0.82% |
| Current Ratio (MRQ) | 17.88 |
| Operating Cash Flow (TTM) | -470.04 M |
| Levered Free Cash Flow (TTM) | -404.95 M |
| Return on Assets (TTM) | -14.94% |
| Return on Equity (TTM) | -21.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vaxcyte, Inc. | Bearish | Bullish |
AIStockmoo Score
1.8
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.75 |
|
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 112.01% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Sep 2024 | 2,198,187 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 140.00 (Needham, 72.71%) | Buy |
| Median | 137.50 (69.63%) | |
| Low | 135.00 (Goldman Sachs, 66.54%) | Buy |
| Average | 137.50 (69.63%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 95.30 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Goldman Sachs | 20 Dec 2024 | 135.00 (66.54%) | Buy | 86.53 |
| Needham | 06 Nov 2024 | 140.00 (72.71%) | Buy | 104.07 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Dec 2024 | Announcement | Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants |
| 12 Nov 2024 | Announcement | Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs |
| 05 Nov 2024 | Announcement | Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |